Literature DB >> 9205053

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

R Rodriguez1, E R Schuur, H Y Lim, G A Henderson, J W Simons, D R Henderson.   

Abstract

Prostate-specific antigen (PSA) is a widely used marker for the diagnosis and management of prostate cancer. Minimal enhancer/promoter constructs derived from the 5' flank of the human PSA gene (prostate-specific enhancer) were inserted into adenovirus type 5 DNA so as to drive the E1A gene, thereby creating a prostate-specific enhancer-containing virus, CN706. E1A was expressed at high levels in CN706-infected human PSA-producing LNCaP cells but not in CN706-infected DU145 cells, which are human prostate cells that do not express PSA. The titer of CN706 was significantly higher in LNCaP cells compared to several human cell lines that do not produce PSA (HBL100, PANC-1, MCF-7, DU145, and OVCAR3). Furthermore, in LNCaP cells, the yield of CN706 was dependent on exogenous androgen (R1881). CN706 destroyed large LNCaP tumors (1 x 10(9) cells) and abolished PSA production in nu/nu mouse xenograft models with a single intratumoral injection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205053

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  104 in total

Review 1.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 3.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 4.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 5.  Gene therapy for urologic cancer.

Authors:  Fernando A Ferrer; Ronald Rodriguez
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 3.092

6.  Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.

Authors:  C-Q Su; J Sham; H-B Xue; X-H Wang; D Chua; Z-F Cui; L-H Peng; L-F Li; L-H Jiang; M-C Wu; Q-J Qian
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-09       Impact factor: 4.553

7.  Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell.

Authors:  Junjie Liu; Lin Fang; Qian Cheng; Liantao Li; Changqing Su; Baofu Zhang; Dongsheng Pei; Jie Yang; Wang Li; Junnian Zheng
Journal:  Cancer Sci       Date:  2012-08-10       Impact factor: 6.716

Review 8.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

Authors:  Marxa L Figueiredo; Makoto Sato; Mai Johnson; Lily Wu
Journal:  Future Oncol       Date:  2006-06       Impact factor: 3.404

Review 9.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

Review 10.  Transcriptionally targeted gene therapy to detect and treat cancer.

Authors:  Lily Wu; Mai Johnson; Makoto Sato
Journal:  Trends Mol Med       Date:  2003-10       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.